The U.S. Patent Trial and Appeal Board ruled last week that the tribal immunity granted to Native American tribes in the U.S. does not shield tribes from patent challenges.
The ruling is a setback for Allergan (NYSE:AGN); the pharmaceutical company transferred patent rights for its blockbuster eye drug, Restasis, to the St. Regis Mohawk Tribe last year in an attempt to avoid inter partes review.
Get the full story at our sister site, Drug Delivery Business News.
The post Patent board rules Mohawk tribe is not immune to challenges over Restasis IP appeared first on MassDevice.